Corcept Therapeutics Inc
CORT
查看详细走势图
37.500USD
+0.970+2.66%
收盘 01/09, 16:00（美东）报价延迟15分钟
3.94B总市值
36.71市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
+2.66%
5天
-1.83%
1月
-56.96%
6月
-47.92%
今年开始到现在
+7.76%
1年
-24.77%
查看详细走势图
TradingKey Corcept Therapeutics Inc股票评分
单位: USD 更新时间: 2026-01-09操作建议
Corcept Therapeutics Inc当前公司基本面数据相对非常健康，最新ESG披露属于行业偏弱水平。增长潜力很大。当前估值合理，在药品行业排名88/159位。机构持股占比非常高，近一月多位分析师给出公司评级为持有。最高目标价91.00。中期看，股价处于下降通道。近一个月，市场表现非常差，但公司基本面和技术面得分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
Corcept Therapeutics Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
看空
Corcept Therapeutics Inc亮点
亮点风险
Corcept Therapeutics Incorporated is a commercial-stage company. The Company is engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol. The Company operates through the discovery, development and commercialization of the pharmaceutical products segment. The Company has marketed Korlym (mifepristone) in the United States for the treatment of patients suffering from Cushings syndrome. The Company’s portfolio of selective cortisol modulators consists of four series totaling approximately 1,000 compounds. Its portfolio of selective cortisol modulators consists of relacorilant, dazucorilant and miricorilant. Korlyms active ingredient, mifepristone, reduces the binding of excess cortisol to the GR, it can modulate the effects of abnormal levels and release patterns of cortisol without compromising cortisols healthy functions and rhythms.
业绩高增长
公司营业收入稳步增长，连续3年增长67.98%
利润高增长
公司净利润处于行业前列，最新年度总收入675.04M美元
估值合理
公司最新PE估值36.71，处于3年历史合理位
机构减仓
最新机构持股79.27M股，环比减少10.00%
CI 精选加拿大股票基金持仓
明星投资者CI 精选加拿大股票基金持仓，最新持仓市值499.00
活跃度降低
近期活跃度降低，过去20天平均换手率-0.34
分析师目标
根据
6
位分析师
持有
评级
91.000
目标均价
+160.37%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Corcept Therapeutics Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Corcept Therapeutics Inc简介
Corcept Therapeutics Incorporated is a commercial-stage company. The Company is engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol. The Company operates through the discovery, development and commercialization of the pharmaceutical products segment. The Company has marketed Korlym (mifepristone) in the United States for the treatment of patients suffering from Cushings syndrome. The Company’s portfolio of selective cortisol modulators consists of four series totaling approximately 1,000 compounds. Its portfolio of selective cortisol modulators consists of relacorilant, dazucorilant and miricorilant. Korlyms active ingredient, mifepristone, reduces the binding of excess cortisol to the GR, it can modulate the effects of abnormal levels and release patterns of cortisol without compromising cortisols healthy functions and rhythms.
公司代码CORT
公司Corcept Therapeutics Inc
CEOBelanoff (Joseph K)
网址https://www.corcept.com/
常见问题
Corcept Therapeutics Inc(CORT)的当前股价是多少？
Corcept Therapeutics Inc(CORT)的当前股价是 37.500。
Corcept Therapeutics Inc的股票代码是什么？
Corcept Therapeutics Inc的股票代码是CORT。
Corcept Therapeutics Inc股票的52周最高点是多少？
Corcept Therapeutics Inc股票的52周最高点是117.330。
Corcept Therapeutics Inc股票的52周最低点是多少？
Corcept Therapeutics Inc股票的52周最低点是32.991。
Corcept Therapeutics Inc的市值是多少？
Corcept Therapeutics Inc的市值是3.94B。
Corcept Therapeutics Inc的净利润是多少？
Corcept Therapeutics Inc的净利润为141.21M。
现在Corcept Therapeutics Inc(CORT)的股票是买入、持有还是卖出？
根据分析师评级，Corcept Therapeutics Inc(CORT)的总体评级为持有，目标价格为91.000。
Corcept Therapeutics Inc(CORT)股票的每股收益（EPS TTM）是多少
Corcept Therapeutics Inc(CORT)股票的每股收益（EPS TTM）是1.022。
相关品种
